Alivus Life Sciences Acquires 76% Stake in IQGenX for ₹91.2 Million
Alivus Life Sciences Limited has announced the acquisition of a 76% majority stake in IQGenX Pharma Private Limited for a consideration of INR 91.2 million. IQGenX, a custom research organization founded in 2016, specializes in formulation development for oral solids, sterile injectables, and ophthalmic solutions across regulated and semi-regulated markets. This acquisition aims to integrate Alivus's API expertise with IQGenX's formulation capabilities, creating an end-to-end platform for complex drug delivery formats. The move is expected to expand Alivus's global customer base, enhance its CDMO services, and focus on niche oncology assets for out-licensing. The deal is subject to customary closing conditions and is anticipated to conclude by the end of the current calendar year.
Key Highlights
- Alivus Life Sciences acquires 76% of IQGenX Pharma for ₹91.2 million.
- Acquisition integrates API strength with formulation development capabilities.
- Expands Alivus's global reach and CDMO service offerings.
- Focus on oncology niche assets and differentiated, out-licensable products.
- Deal expected to close by year-end, subject to closing conditions.
Price Impact
More from ALIVUS